Psoriatic Arthritis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PSORAS MCID: PSR001 MIFTS: 63	Psoriatic Arthritis (PSORAS) Categories: Bone diseases, Genetic diseases, Immune diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Psoriatic Arthritis

MalaCards integrated aliases for Psoriatic Arthritis:

Name: Psoriatic Arthritis ⁵⁷ ¹¹ ⁴² ⁷⁵ ⁷³ ⁴¹ ¹⁴ ¹⁶ ⁷⁵ ³³

Psoriatic Arthritis, Susceptibility to ⁵⁷ ²⁸ ¹² ⁵

Psoriatic Arthropathy ¹¹ ⁴² ⁷³ ³³

Arthropathic Psoriasis ¹¹ ⁴² ³¹

Arthritis, Psoriatic ⁴³ ⁷¹

Arthritis, Psoriatic, Susceptibility to ³⁸

Psoriasis Arthropathica ⁷³

Arthritis Psoriatica ¹¹

Arthritic Psoriasis ⁷³

Arthritis Psoriatic ⁵³

Psoras ⁷³

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases Immune diseases Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the skin and subcutaneous tissue

Papulosquamous disorders

Psoriasis

Arthropathic psoriasis

ICD11: ³³

Diseases of the musculoskeletal system or connective tissue

Arthropathies

Inflammatory arthropathies

Psoriatic arthritis

Other specified psoriatic arthritis

Psoriatic arthritis, unspecified

External Ids:

Disease Ontology ¹¹ DOID:9008

OMIM® ⁵⁷ 607507

ICD9CM ³⁴ 696.0

MeSH ⁴³ D015535

NCIt ⁴⁹ C61277

SNOMED-CT ⁶⁸ 33339001

ICD10 ³¹ L40.5

MedGen ⁴⁰ C1835223 C1843772

EFO ¹⁶ EFO_0003778

ICD11 ³³ 868183264 868183264/other 868183264/unspecified

UMLS ⁷¹ C0003872

Sources

Summaries for Psoriatic Arthritis

MedlinePlus Genetics: ⁴² Psoriatic arthritis is a condition involving joint inflammation (arthritis) that usually occurs in combination with a skin disorder called psoriasis. Psoriasis is a chronic inflammatory condition characterized by patches of red, irritated skin that are often covered by flaky white scales. People with psoriasis may also have changes in their fingernails and toenails, such as nails that become pitted or ridged, crumble, or separate from the nail beds.Signs and symptoms of psoriatic arthritis include stiff, painful joints with redness, heat, and swelling in the surrounding tissues. When the hands and feet are affected, swelling and redness may result in a "sausage-like" appearance of the fingers or toes (dactylitis).In most people with psoriatic arthritis, psoriasis appears before joint problems develop. Psoriasis typically begins during adolescence or young adulthood, and psoriatic arthritis usually occurs between the ages of 30 and 50. However, both conditions may occur at any age. In a small number of cases, psoriatic arthritis develops in the absence of noticeable skin changes.Psoriatic arthritis may be difficult to distinguish from other forms of arthritis, particularly when skin changes are minimal or absent. Nail changes and dactylitis are two features that are characteristic of psoriatic arthritis, although they do not occur in all cases.Psoriatic arthritis is categorized into five types: distal interphalangeal predominant, asymmetric oligoarticular, symmetric polyarthritis, spondylitis, and arthritis mutilans.The distal interphalangeal predominant type affects mainly the ends of the fingers and toes. The distal interphalangeal joints are those closest to the nails. Nail changes are especially frequent with this form of psoriatic arthritis.The asymmetric oligoarticular and symmetric polyarthritis types are the most common forms of psoriatic arthritis. The asymmetric oligoarticular type of psoriatic arthritis involves different joints on each side of the body, while the symmetric polyarthritis form affects the same joints on each side. Any joint in the body may be affected in these forms of the disorder, and symptoms range from mild to severe.Some individuals with psoriatic arthritis have joint involvement that primarily involves spondylitis, which is inflammation in the joints between the vertebrae in the spine. Symptoms of this form of the disorder involve pain and stiffness in the back or neck, and movement is often impaired. Joints in the arms, legs, hands, and feet may also be involved.The most severe and least common type of psoriatic arthritis is called arthritis mutilans. Fewer than 5 percent of individuals with psoriatic arthritis have this form of the disorder. Arthritis mutilans involves severe inflammation that damages the joints in the hands and feet, resulting in deformation and movement problems. Bone loss (osteolysis) at the joints may lead to shortening (telescoping) of the fingers and toes. Neck and back pain may also occur.

MalaCards based summary: Psoriatic Arthritis, also known as psoriatic arthritis, susceptibility to, is related to spondyloarthropathy 1 and juvenile rheumatoid arthritis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Psoriatic Arthritis is LTA (Lymphotoxin Alpha), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Methotrexate and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

MedlinePlus: ⁴¹ Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get them on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people with psoriasis have psoriatic arthritis. It causes pain, stiffness, and swelling of the joints. It is often mild, but can sometimes be serious and affect many joints. The joint and skin problems don't always happen at the same time. Your doctor will do a physical exam and imaging tests to diagnose psoriatic arthritis. There is no cure, but medicines can help control inflammation and pain. In rare cases, you might need surgery to repair or replace damaged joints.

UniProtKB/Swiss-Prot: ⁷³ An inflammatory, seronegative arthritis associated with psoriasis. It is a heterogeneous disorder ranging from a mild, non-destructive disease to a severe, progressive, erosive arthropathy. Five types of psoriatic arthritis have been defined: asymmetrical oligoarthritis characterized by primary involvement of the small joints of the fingers or toes; asymmetrical arthritis which involves the joints of the extremities; symmetrical polyarthritis characterized by a rheumatoid like pattern that can involve hands, wrists, ankles, and feet; arthritis mutilans, which is a rare but deforming and destructive condition; arthritis of the sacroiliac joints and spine (psoriatic spondylitis).

OMIM®: ⁵⁷ Psoriasis (177900) is a chronic inflammatory skin disease that may have an autoimmune basis. The disorder has a strong but complex genetic basis, with a concordance rate of 50 to 70% among monozygotic twins. Psoriatic arthritis affects more than 10% of patients with psoriasis and, in most cases, there is an association between the severity of the arthritis and the skin involvement (Gudjonsson et al., 2002). (607507) (Updated 08-Dec-2022)

Disease Ontology: ¹¹ An arthritis that is characterized by joint inflammation that usually occurs in combination with psoriasis.

Wikipedia ⁷⁵ Psoriatic arthritis: Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...

Psoriatic arthritis: Psoriatic arthritis is a long-term inflammatory arthritis that occurs in people affected by the... more...

Sources

Related Diseases for Psoriatic Arthritis

Diseases related to Psoriatic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 946)

#	Related Disease	Score	Top Affiliating Genes
1	spondyloarthropathy 1	33.4	TNFSF11 TNFRSF1B TNF NOD2 MMP3 IL1B
2	juvenile rheumatoid arthritis	32.4	TNFRSF1B TNF PTPN22 LTA IL1B HLA-DRB1
3	psoriasis	32.4	TNFRSF1B TNF SELE S100A12 PTPN22 NOD2
4	arthritis	32.4	TNIP1 TNFSF11 TNFRSF1B TNF S100A12 PTPN22
5	spondylitis	32.2	TNFSF11 TNF NOD2 MICA LTA IL1B
6	arthropathy	32.1	TNFSF11 TNF NOD2 MMP3 MICA LTA
7	osteoarthritis	31.9	TNFSF11 TNF MMP3 IL1B CRP COMP
8	synovitis	31.9	TNFSF11 TNF SELE MMP3 IL1B CRP
9	enthesopathy	31.9	TNF HLA-B CRP
10	uveitis	31.8	TNF NOD2 LTA IL1B HLA-DRB1 HLA-B
11	skin disease	31.8	TNF SELE NOD2 MIR146A IL1B IL13
12	tenosynovitis	31.8	TNF NOD2 MMP3 IL1B CRP
13	reactive arthritis	31.7	TNF HLA-B CRP COMP
14	ankylosis	31.7	TNFSF11 TNF CRP
15	spondyloarthropathy	31.7	TNFSF11 TNF NOD2 IL1B HLA-DRB1 HLA-C
16	fibromyalgia	31.7	TNF IL1B CRP
17	gout	31.6	TNF IL1B HLA-B CRP
18	spondylarthropathy	31.5	TNF LTA CRP
19	exanthem	31.5	TNF IL1B HLA-B CRP
20	atherosclerosis susceptibility	31.5	TNF SELE IL1B CRP
21	periostitis	31.5	TNF IL1B CRP
22	bowel dysfunction	31.5	TNF NOD2 IL1B CRP
23	nasopharyngitis	31.5	TNF IL13 CRP
24	autoimmune disease	31.5	TNFRSF1B TNF PTPN22 MIR146A LTA IL1B
25	inflammatory bowel disease 1	31.5	TNF NOD2 IL1B
26	rheumatoid arthritis	31.4	TNIP1 TNFSF11 TNFRSF1B TNF SELE S100A12
27	lipid metabolism disorder	31.4	TNF SELE IL1B CRP
28	crohn's disease	31.4	TNF S100A12 NOD2 IL1B IL13 CRP
29	anterior uveitis	31.4	TNF IL1B HLA-DRB1 HLA-B CRP
30	bursitis	31.4	TNF IL1B CRP
31	back pain	31.4	MMP3 IL1B CRP
32	dermatitis	31.4	TNF NOD2 IL1B IL13
33	sapho syndrome	31.3	TNF NOD2 CRP
34	viral infectious disease	31.3	TNF IL1B IL13 HLA-B
35	systemic scleroderma	31.2	TNF IL1B IL13 HLA-DRB1 CRP
36	cartilage disease	31.2	TNF MMP3 IL1B CRP COMP
37	diarrhea	31.2	TNF NOD2 IL1B IL13
38	ulcerative colitis	31.2	TNF S100A12 NOD2 IL1B IL13 HLA-DRB1
39	vasculitis	31.2	TNFRSF1B TNF SELE IL1B HLA-DRB1 HLA-B
40	covid-19	31.1	TNF IL1B HLA-C CRP
41	thyroiditis	31.1	TNF PTPN22 IL1B HLA-DRB1 CRP
42	pyoderma	31.1	TNF NOD2 IL1B CRP
43	leishmaniasis	31.1	TNF LTA IL1B IL13
44	chickenpox	31.1	TNF IL1B CRP
45	vascular disease	31.1	TNF SELE MMP3 MIR146A CRP
46	sleep disorder	31.1	TNF IL1B CRP
47	pyoderma gangrenosum	31.1	TNF NOD2 IL1B
48	severe acute respiratory syndrome	31.0	TNF IL1B HLA-C CRP
49	bone inflammation disease	31.0	TNFSF11 TNF PTPN22 MMP3 MIR146A IL1B
50	periodontitis	31.0	TNFSF11 TNF MMP3 IL1B CRP

Graphical network of the top 20 diseases related to Psoriatic Arthritis:

Sources

Symptoms & Phenotypes for Psoriatic Arthritis

Clinical features from OMIM®:

607507 (Updated 08-Dec-2022)

UMLS symptoms related to Psoriatic Arthritis:

back pain; sciatica; muscle cramp

GenomeRNAi Phenotypes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

²⁵ (show all 21)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	9.68	MICA
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-118	9.68	HLA-B HLA-C
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.68	MICA
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-124	9.68	HLA-C
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.68	MICA
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.68	HLA-C
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.68	SELE
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-162	9.68	HLA-C
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	9.68	SELE
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-19	9.68	SELE
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	9.68	NOD2
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-26	9.68	SELE
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-36	9.68	NOD2
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-38	9.68	SELE
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-39	9.68	SELE
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-46	9.68	MICA
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.68	HLA-C
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-57	9.68	MICA
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.68	HLA-B HLA-C
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	9.68	MICA
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	9.68	HLA-C

MGI Mouse Phenotypes related to Psoriatic Arthritis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.28	COMP CRP IL13 IL1B LTA MIR146A
2	growth/size/body region	MP:0005378	10.25	COMP HLA-B HLA-C HLA-DRB1 IL13 IL1B
3	endocrine/exocrine gland	MP:0005379	10.07	HLA-B HLA-C IL13 LTA NOD2 PTPN22
4	immune system	MP:0005387	10.06	COMP CRP HLA-B HLA-C IL13 IL1B
5	no phenotypic analysis	MP:0003012	10	HLA-B HLA-C IL13 MIR146A TNF TNFSF11
6	cardiovascular system	MP:0005385	10	COMP CRP HLA-B HLA-C IL1B LTA
7	digestive/alimentary	MP:0005381	9.92	HLA-B HLA-C IL13 NOD2 PTPN22 TNF
8	skeleton	MP:0005390	9.7	COMP HLA-DRB1 IL13 IL1B LTA MIR146A
9	hematopoietic system	MP:0005397	9.47	HLA-B HLA-C IL13 IL1B LTA MIR146A

Sources

Drugs & Therapeutics for Psoriatic Arthritis

Drugs for Psoriatic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Golimumab

Approved

Phase 4

476181-74-5

Adalimumab

Approved, Experimental

Phase 4

331731-18-1

Upadacitinib

Approved, Investigational

Phase 4

1310726-60-3

76829165 58557659

Tofacitinib

Approved, Investigational

Phase 4

477600-75-2

9926791

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Etanercept

Approved, Investigational

Phase 4

185243-69-0

Leflunomide

Approved, Investigational

Phase 4

75706-12-6

3899

Sulfasalazine

Approved

Phase 4

599-79-1

5353980 5339 5359476

Certolizumab pegol

Approved

Phase 4

428863-50-7

Ixekizumab

Approved, Investigational

Phase 4

1143503-69-8

Thalidomide

Approved, Investigational, Withdrawn

Phase 4

50-35-1

5426

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Hormones

Phase 4

Hormone Antagonists

Phase 4

Immunosuppressive Agents

Phase 4

Melanocyte-Stimulating Hormones

Phase 4

Adrenocorticotropic Hormone

Phase 4

beta-Endorphin

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Neuroprotective Agents

Phase 4

Antiemetics

Phase 4

glucocorticoids

Phase 4

Methylprednisolone Acetate

Phase 4

584547

Protective Agents

Phase 4

Methylene diphosphonate

Phase 4

Diphosphonates

Phase 4

Immunologic Factors

Phase 4

Dermatologic Agents

Phase 4

Protein Kinase Inhibitors

Phase 4

Tumor Necrosis Factor Inhibitors

Phase 4

Janus Kinase Inhibitors

Phase 4

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Immune Checkpoint Inhibitors

Phase 4

Gastrointestinal Agents

Phase 4

Vaccines

Phase 4

Anti-Bacterial Agents

Phase 4

Angiogenesis Inhibitors

Phase 4

Lactitol

Approved, Investigational

Phase 3

585-86-4

157355

Ustekinumab

Approved, Investigational

Phase 3

815610-63-0

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Interventional clinical trials:

(show top 50) (show all 446)

#	Name	Status	NCT ID	Phase	Drugs
1	Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA)	Unknown status	NCT01939132	Phase 4	Open label H.P. Acthar Gel
2	Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB	Unknown status	NCT04106804	Phase 4	Abatacept 125 MG/ML
3	Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis	Unknown status	NCT02132234	Phase 4	Etanercept;Adalimumab;Certolizumab;Infliximab
4	Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis	Unknown status	NCT01223976	Phase 4
5	Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes	Unknown status	NCT04515732	Phase 4	Apremilast Oral Tablet
6	A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis	Completed	NCT03733925	Phase 4	Golimumab
7	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks	Completed	NCT02798211	Phase 4	Secukinumab 300 mg;Secukinumab 150 mg
8	A Phase 4, Multicenter, Single-Arm, Open-Label Study to Evaluate the Impact of Apremilast (CC-10004) Monotherapy on MRI Outcomes in Subjects With Active Psoriatic Arthritis	Completed	NCT03783026	Phase 4	CC-10004
9	TNF-α Blockade for Psoriatic Arthritis - A Clinical and MRI Study, and the Effects on Cytokine and Cardiovascular Risk Profile	Completed	NCT00432406	Phase 4	Infliximab;Etanercept
10	An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma	Completed	NCT04183881	Phase 4	Brodalumab 210mg SC
11	A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY	Completed	NCT02148640	Phase 4	Innovator infliximab;Biosimilar infliximab
12	Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®	Completed	NCT00127842	Phase 4	Etanercept
13	A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Completed	NCT03151551	Phase 4	Ixekizumab;Adalimumab
14	Enbrel® in Psoriatic Arthritis	Completed	NCT00111124	Phase 4	Enbrel®
15	A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS	Completed	NCT00245960	Phase 4	etanercept;Placebo
16	Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)	Completed	NCT03419650	Phase 4	ACTHar
17	Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice	Completed	NCT01147874	Phase 4
18	A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)	Completed	NCT02814175	Phase 4	methotrexate (MTX)
19	A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis	Completed	NCT05000086	Phase 4	99Tc methylene diphosphonate
20	Can New Imaging- and Biomarkers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Psoriatic Arthritis Patients Receiving Adalimumab?	Completed	NCT01465438	Phase 4	Adalimumab
21	Microarray Analysis of Peripheral Blood and Tissues of Patients With Immune Mediated Inflammatory Diseases	Completed	NCT00462072	Phase 4	Infliximab
22	Clinical Effectiveness of Symptomatic Therapy Compared to Standard Step up Care for the Treatment of Low Impact Psoriatic Oligoarthritis: a 2 Arm Parallel Group Feasibility Study	Completed	NCT03797872	Phase 4	Methotrexate;Sulfasalazine;Leflunomide;Methylprednisolone;Triamcinolone
23	TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies	Completed	NCT00133315	Phase 4	Infliximab;Etanercept;Adalimumab
24	A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy	Completed	NCT00161655	Phase 4	Etanercept;Methotrexate
25	Clinical Effectiveness of Standard Step up Care (Methotrexate) Compared to Early Combination DMARD Therapy With Standard Step up Care Compared to Early Use of TNF Inhibitors With Standard Step up Care for the Treatment of Moderate to Severe Psoriatic Arthritis: a 3-arm Parallel Group Randomised Controlled Trial.	Recruiting	NCT03739853	Phase 4	Methotrexate;Sulfasalazine;Leflunomide;Adalimumab
26	A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease	Recruiting	NCT04929210	Phase 4	Guselkumab;Placebo
27	Prevention of Metacarpophalangeal Joints Structure Damage in Patients With Psoriatic Arthritis Using Secukinumab	Recruiting	NCT03623867	Phase 4	Secukinumab;Placebo
28	Monitoring Nail Changes in Patients With Psoriatic Disease Treated With Etanercept Using Non- Invasive Optical Coherence Tomography	Recruiting	NCT05135312	Phase 4	Etanercept
29	The SARS-CoV-2 Vaccine Response and Safety in Rheumatology Patients and the Influence of Temporary Interruptions in Immunomodulatory Therapy	Recruiting	NCT05080218	Phase 4	Upadacitinib;Abatacept;Secukinumab;Tofacitinib;TNF Inhibitor;Canakinumab Injection;Baricitinib;Ixekizumab
30	A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or ≤ 1 Conventional Synthetic DMARD	Active, not recruiting	NCT03747939	Phase 4	Apremilast (CC-10004)
31	EBIO - Enthesitis Biopsy Study	Active, not recruiting	NCT04887597	Phase 4	Secukinumab
32	Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Who Have an Inadequate Skin Response to Anti-IL23 Therapy	Not yet recruiting	NCT05499416	Phase 4	Bimekizumab
33	Validation of the PsASon ULtrasound Scores in Patients With Psoriatic Arthritis Undergoing TReatment With Apremilast	Withdrawn	NCT04102449	Phase 4	Apremilast
34	A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis	Withdrawn	NCT02558361	Phase 4	Treatment with Apremilast
35	SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE	Withdrawn	NCT04417114	Phase 4	Rosuvastatin
36	Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis	Unknown status	NCT03191539	Phase 3	Apremilast
37	An Investigator-initiated Double-blind, Parallel-group Randomised Controlled Trial of GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA Using Clinical and Whole Body MRI Outcomes: the GOLMePsA Study.	Unknown status	NCT04108468	Phase 3	Golimumab;Methotrexate
38	MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52-week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non-steroidal Anti-inflammatory Drugs (NSAIDs)	Completed	NCT02721966	Phase 3	Secukinumab and Placebo
39	A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis	Completed	NCT04109976	Phase 3	Bimekizumab
40	A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis	Completed	NCT01989468	Phase 3
41	A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor	Completed	NCT01882439	Phase 3	Tofacitinib
42	A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis	Completed	NCT01871649	Phase 3	golimumab;methotrexate
43	A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis	Completed	NCT02662985	Phase 3	AIN457 (secukinumab);Placebo
44	An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma	Completed	NCT02052609	Phase 3	KHK4827 140mg SC;KHK4827 210mg SC
45	A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity	Completed	NCT03066609	Phase 3	Secukinumab 150 mg s.c.;Secukinumab 300 mg s.c.;Placebo
46	A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept	Completed	NCT01901185	Phase 3	Etanercept / Autoinjector A
47	Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy	Completed	NCT00646178	Phase 3	adalimumab;placebo for adalimumab
48	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Psoriatic Arthritis	Completed	NCT04209205	Phase 3	Secukinumab;Placebo
49	Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis	Completed	NCT03736161	Phase 3	Group A- Tofacitinib;Group B- Methotrexate
50	A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis	Completed	NCT02986139	Phase 3	Commercial Formulation Etanercept;New Formulation Etanercept

Search NIH Clinical Center for Psoriatic Arthritis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Auranofin

Aurothioglucose

Etanercept

Cochrane evidence based reviews: arthritis, psoriatic

Sources

Genetic Tests for Psoriatic Arthritis

Genetic tests related to Psoriatic Arthritis:

#	Genetic test	Affiliating Genes
1	Psoriatic Arthritis, Susceptibility to ²⁸	LTA

Sources

Anatomical Context for Psoriatic Arthritis

Organs/tissues related to Psoriatic Arthritis:

MalaCards : Skin, Bone, T Cells, Endothelial, Liver, Breast, Bone Marrow

Sources

Publications for Psoriatic Arthritis

Articles related to Psoriatic Arthritis:

(show top 50) (show all 11334)

#	Title	Authors	PMID	Year
1	Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. ⁶² ⁵⁷ ⁵	Balding J...FitzGerald O	12746914	2003
2	CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. ⁵³ ⁶² ⁵⁷	Rahman P...Gladman DD	12879366	2003
3	Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. ⁵³ ⁶² ⁵⁷	Ritchlin CT...Schwarz EM	12639988	2003
4	Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. ⁶² ⁵⁷	Huffmeier U...Reis A	18800148	2009
5	PSORS2 markers are not associated with psoriatic arthritis in the Italian population. ⁶² ⁵⁷	Giardina E...Novelli G	16733365	2006
6	A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. ⁶² ⁵⁷	Karason A...Gulcher JR	12474146	2003
7	HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. ⁶² ⁵⁷	Gudjonsson JE...Valdimarsson H	11841557	2002
8	HLA-C locus alleles in patients with psoriatic arthritis (PsA). ⁶² ⁵⁷	Gladman DD...Wade JA	10321964	1999
9	The causal relationship between psoriasis, psoriatic arthritis, and inflammatory bowel diseases. ⁶² ⁴¹	Sun Y...Zhang J	36443384	2022
10	Four emerging immune cellular blood phenotypes associated with disease duration and activity established in Psoriatic Arthritis. ⁶² ⁴¹	Skougaard M...Kristensen LE	36447253	2022
11	Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3intCD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies. ⁶² ⁴¹	Pouw JNJ...Boes MM	36450783	2022
12	The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility. ⁶² ⁴⁶	Chatzikyriakidou A...Drosos AA	20500689	2010
13	Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. ⁵	Lee YH...Nath SK	16418737	2006
14	An association between asthma and TNF-308G/A polymorphism: meta-analysis. ⁵	Aoki T...Noguchi E	16865291	2006
15	Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. ⁵	Shin HD...Park CS	14681301	2004
16	Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. ⁵	Rainero I...Pinessi L	14718719	2004
17	Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. ⁵	Krikovszky D...Madacsy L	12485196	2002
18	Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. ⁵	Ozaki K...Tanaka T	12426569	2002
19	Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. ⁵	Witte JS...Hall JM	11896460	2002
20	Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. ⁵	Szalai C...Csaszar A	11826025	2002
21	Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. ⁵	Quasney MW...McArthur J	11506397	2001
22	Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. ⁵	Moraes MO...Sarno EN	11261930	2001
23	Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. ⁵	Mira JP...Dhainaut JF	10450718	1999
24	Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. ⁵	Ma JJ...Uchiyama T	9818939	1998
25	Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. ⁵⁷	Enerback C...Swanbeck G	9347803	1997
26	Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. ⁵	Cox A...Duff GW	8056188	1994
27	Lipoma arborescens co-existing with psoriatic arthritis releases tumour necrosis factor alpha and matrix metalloproteinase 3. ⁵³ ⁶²	Fraser AR...McInnes IB	20237127	2010
28	Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. ⁵³ ⁶²	Duffin KC...Krueger GG	20415816	2010
29	The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. ⁵³ ⁶²	Leeb BF...Broll H	19904485	2010
30	Infliximab and anterior optic neuropathy: case report and review of the literature. ⁵³ ⁶²	Chan JW...Castellanos A	19916016	2010
31	Possible association between NOD2 variants and joint surgery in psoriatic arthritis. ⁵³ ⁶²	Graell E...Canete JD	20346235	2010
32	A case of tuberculous arthritis following the use of etanercept. ⁵³ ⁶²	Choi SW...Cho SD	19949742	2009
33	Association between IL13 polymorphisms and psoriatic arthritis is modified by smoking. ⁵³ ⁶²	Duffin KC...Krueger GG	19554022	2009
34	Psoriatic arthritis: pharmacoeconomic considerations. ⁵³ ⁶²	Olivieri I...de Portu S	19691929	2009
35	Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? ⁵³ ⁶²	Nannini C...Lally EV	19479708	2009
36	Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. ⁵³ ⁶²	Kaymakcalan Z...Sasso EH	19188093	2009
37	Spondyloarthropathies: Targeted therapy for psoriatic arthritis. ⁵³ ⁶²	Gladman DD	19412187	2009
38	Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. ⁵³ ⁶²	Pomerantz RG...Qureshi AA	19363860	2009
39	Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. ⁵³ ⁶²	Massarotti M...Marasini B	19505409	2009
40	Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? ⁵³ ⁶²	Kocharla L...Mongey AB	19151120	2009
41	Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. ⁵³ ⁶²	Ganguly S	19222252	2009
42	Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. ⁵³ ⁶²	Perlmutter A...Menter A	19016693	2009
43	Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. ⁵³ ⁶²	Kucharekova M...Poblete-Gutierrez P	18986481	2008
44	Etanercept in therapy multiresistant overlapping pityriasis lichenoides. ⁵³ ⁶²	Nikkels AF...Pierard GE	19112768	2008
45	Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. ⁵³ ⁶²	Cassano N...Vena GA	19036225	2008
46	Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. ⁵³ ⁶²	Fantuzzi F...Girolomoni G	18694376	2008
47	Spinal epidural abscess associated with infliximab treatment for psoriatic arthritis. Case report. ⁵³ ⁶²	Smith AP...O'Toole JE	18928222	2008
48	Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. ⁵³ ⁶²	Schrodi SJ	20476959	2008
49	Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. ⁵³ ⁶²	Strober B...Dann F	18503600	2008
50	[First manifestation of psoriasis vulgaris in tumor necrosis factor receptor-associated periodic syndrome during treatment with etanercept]. ⁵³ ⁶²	Boms S...Enk A	18210001	2008

Sources

Genes for Psoriatic Arthritis

Genes related to Psoriatic Arthritis (2 elite genes):

(show top 50) (show all 56)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	LTA	Lymphotoxin Alpha	Protein Coding	708.09	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Risk factor ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	12426569 12746914 14681301
2	MIR146A	MicroRNA 146a	RNA Gene	365.64	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	20500689
3	TNF	Tumor Necrosis Factor	Protein Coding	62.14	Risk factor ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	10450718 11261930 9818939 (more) 11896460 14681301 16865291 11506397 8056188 12485196 11826025 12746914 14718719 16418737 16284098 9326391 15838232 14678719 14967799 16763453 15251081 11874829 17120686 12728284 16782734 16402631 12635469 18694376 17613555 16045835 15194570 12426660 11830425 19479708 18381787 16539822 18240258 14513116 18065252 12011375 8868110 12639988 15180471 15450340 15933486 16310398 16542122 17853309 17921804 18986481 19112768 19075965 19188093 19412187 19505409 19916016 15567814 15823500 15627075 15201597 14616825 12951580 11121160 20477266 20237127 15580154 15377173 15194567 15095759 15011134 12894133 12463461 12428265 11990861 18360621 17644547 18075630 17911474 17828356 17956013 17530646 17328057 16134723 19016693 18438853 17827183 12463467 11336571 19904485 19949742 19691929 19363860 19151120 18928222 16133634 18214362 17560312 17117328 16150792 16843030 16258581 15691217 15675890 11405771 19222252 19036225 17364199 17786135 16720636 16566659 16265699 19080986 18210001
4	MICA	MHC Class I Polypeptide-Related Sequence A	Protein Coding	31.06	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
5	LOC100287329	Uncharacterized LOC100287329	RNA Gene	25	Risk factor ⁵	12426569 12746914 14681301
6	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	24.41	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
7	CRP	C-Reactive Protein	Protein Coding	24.07	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18503600 2059079 15260390 (more) 17179176 16513489
8	TNIP1	TNFAIP3 Interacting Protein 1	Protein Coding	22.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
9	S100A12	S100 Calcium Binding Protein A12	Protein Coding	21.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
10	HLA-C	Major Histocompatibility Complex, Class I, C	Protein Coding	21.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15539411 16313304 20476959
11	TNFRSF1B	TNF Receptor Superfamily Member 1B	Protein Coding	20.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17502870 19222252 17394851 (more) 12011375
12	NOD2	Nucleotide Binding Oligomerization Domain Containing 2	Protein Coding	20.32	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15539411 12879366 15251084 (more) 15140210 16255050 20346235 15468360 16402184
13	TNFSF11	TNF Superfamily Member 11	Protein Coding	20.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20201244 17370327
14	PTPN22	Protein Tyrosine Phosphatase Non-Receptor Type 22	Protein Coding	20.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15934099
15	IL1B	Interleukin 1 Beta	Protein Coding	19.92	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12890860 8079828 15958769 (more) 8079829 8882136 16829497 16846531
16	MMP3	Matrix Metallopeptidase 3	Protein Coding	19.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11796404 20237127 16278151
17	COMP	Cartilage Oligomeric Matrix Protein	Protein Coding	18.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15059267 16635048
18	SELE	Selectin E	Protein Coding	18.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7686370 8546722 14513116
19	IL13	Interleukin 13	Protein Coding	18.08	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11796407 20415816 19554022
20	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	18.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17728335
21	IL1A	Interleukin 1 Alpha	Protein Coding	16.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16829497
22	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	16.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14758777
23	CD58	CD58 Molecule	Protein Coding	16.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12384938
24	IL23R	Interleukin 23 Receptor	Protein Coding	15.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	IL6	Interleukin 6	Protein Coding	15.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	TLR2	Toll Like Receptor 2	Protein Coding	15.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17183618
27	MMP1	Matrix Metallopeptidase 1	Protein Coding	15.23	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14523226
28	IL1RAPL2	Interleukin 1 Receptor Accessory Protein Like 2	Protein Coding	15.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10776688 16378499
29	IL23A	Interleukin 23 Subunit Alpha	Protein Coding	14.92	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	IL10	Interleukin 10	Protein Coding	14.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	NFKBIA	NFKB Inhibitor Alpha	Protein Coding	14.74	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17701919 16142871
32	ANGPT2	Angiopoietin 2	Protein Coding	14.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15201594 12563678
33	TNFRSF11B	TNF Receptor Superfamily Member 11b	Protein Coding	14.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20201244
34	CARD14	Caspase Recruitment Domain Family Member 14	Protein Coding	13.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	13.62	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	13.58	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	IL1RN	Interleukin 1 Receptor Antagonist	Protein Coding	13.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	IL1R1	Interleukin 1 Receptor Type 1	Protein Coding	12.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	12.89	DISEASES inferred ¹⁴ ¹⁴
40	IL12B	Interleukin 12B	Protein Coding	12.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	IL7	Interleukin 7	Protein Coding	12.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	MMP9	Matrix Metallopeptidase 9	Protein Coding	12.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	IRAK1	Interleukin 1 Receptor Associated Kinase 1	Protein Coding	12.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	IRAK1::MIR146A ⁴⁶	MIR146A Macro RNA (hsa-miR-146a) targets IRAK1
44	TIMP1	TIMP Metallopeptidase Inhibitor 1	Protein Coding	12.22	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	APOA1	Apolipoprotein A1	Protein Coding	11.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	MMP2	Matrix Metallopeptidase 2	Protein Coding	11.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	NFKB1	Nuclear Factor Kappa B Subunit 1	Protein Coding	11.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	CCHCR1	Coiled-Coil Alpha-Helical Rod Protein 1	Protein Coding	11.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	SLC22A4	Solute Carrier Family 22 Member 4	Protein Coding	11.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	JAM3	Junctional Adhesion Molecule 3	Protein Coding	11.16	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)

Sources

Variations for Psoriatic Arthritis

ClinVar genetic disease variations for Psoriatic Arthritis:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	LTA, LOC100287329	NM_000595.4(LTA):c.-10+90A>G	SNV	Risk Factor	14380	rs909253	GRCh37: 6:31540313-31540313 GRCh38: 6:31572536-31572536
2	TNF	NM_000594.3(TNF):c.-488G>A	SNV	Risk Factor	225964	rs1800629	GRCh37: 6:31543031-31543031 GRCh38: 6:31575254-31575254
3	NOD2	NM_001370466.1(NOD2):c.2641G>C (p.Gly881Arg)	SNV	Uncertain Significance	4692	rs2066845	GRCh37: 16:50756540-50756540 GRCh38: 16:50722629-50722629
4	NOD2	NM_001370466.1(NOD2):c.2183C>T (p.Ala728Val)	SNV	Uncertain Significance	319462	rs61747625	GRCh37: 16:50746086-50746086 GRCh38: 16:50712175-50712175
5	NOD2	NM_001370466.1(NOD2):c.2631G>A (p.Leu877=)	SNV	Uncertain Significance	319472	rs142559533	GRCh37: 16:50753917-50753917 GRCh38: 16:50720006-50720006
6	NOD2	NM_001370466.1(NOD2):c.1970G>A (p.Arg657Gln)	SNV	Uncertain Significance	779017	rs114664276	GRCh37: 16:50745873-50745873 GRCh38: 16:50711962-50711962
7	NOD2	NM_001370466.1(NOD2):c.2116G>A (p.Val706Met)	SNV	Uncertain Significance	992540	rs746055479	GRCh37: 16:50746019-50746019 GRCh38: 16:50712108-50712108
8	NOD2	NM_001370466.1(NOD2):c.963A>G (p.Leu321=)	SNV	Uncertain Significance	1675106		GRCh37: 16:50744866-50744866 GRCh38: 16:50710955-50710955
9	NOD2	NM_001370466.1(NOD2):c.1753G>A (p.Ala585Thr)	SNV	Uncertain Significance	4700	rs104895438	GRCh37: 16:50745656-50745656 GRCh38: 16:50711745-50711745
10	NOD2	NM_001370466.1(NOD2):c.2782G>A (p.Val928Ile)	SNV	Likely Benign	97869	rs5743291	GRCh37: 16:50757276-50757276 GRCh38: 16:50723365-50723365

Sources

Expression for Psoriatic Arthritis

Search GEO for disease gene expression data for Psoriatic Arthritis.

Sources

Pathways for Psoriatic Arthritis

Pathways related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.58	CRP HLA-B HLA-C HLA-DRB1 IL13 IL1B
2	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.2	TNFSF11 TNFRSF1B TNF PTPN22 LTA IL1B
3	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	12.81	TNFSF11 TNFRSF1B TNF S100A12 NOD2 MMP3
4	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.53	TNF LTA IL1B IL13 HLA-C HLA-B
5	TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions ⁶⁵ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ TNFs bind their physiological receptors ⁶⁶ TRAF Pathway ⁶⁴	12.53	TNIP1 TNFSF11 TNFRSF1B TNF LTA IL1B
6	NF-kappaB Signaling ³	12.4	TNIP1 TNFSF11 TNFRSF1B TNF PTPN22 IL1B
7	Interleukin-1 family signaling ⁶⁶ Show member pathways Interleukin-1 signaling ⁶⁶ Interleukin-18 signaling ⁶⁶ Interleukin-38 signaling ⁶⁶	12.38	S100A12 NOD2 IL1B IL13
8	Neuroinflammation and glutamatergic signaling ⁷⁴	11.91	TNFRSF1B TNF LTA IL1B IL13
9	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.75	TNFRSF1B TNF MMP3 IL1B IL13
10	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.7	IL1B LTA TNF TNFRSF1B
11	Innate Lymphoid Cells Differentiation ⁶⁵	11.68	IL13 IL1B LTA TNF
12	Apoptosis and survival Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic TNFs/NF-kB/IAP pathway ²²	11.65	TNFSF11 TNFRSF1B TNF
13	Lung fibrosis ⁷⁴	11.58	TNF IL1B IL13
14	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.56	TNF SELE MMP3 IL1B
15	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.55	TNF NOD2 IL13
16	IL 10 signaling pathway ⁶⁷	11.53	TNFSF11 TNF LTA IL1B
17	Transcription_NF-kB signaling pathway ²²	11.49	TNFRSF1B TNF LTA
18	Interleukin-10 signaling ⁶⁶	11.42	IL1B TNF TNFRSF1B
19	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.4	TNFSF11 TNF IL1B
20	CTL Mediated Apoptosis ⁶⁴	11.31	HLA-DRB1 HLA-C HLA-B
21	Development and heterogeneity of the ILC family ⁷⁴	11.22	TNF IL1B IL13
22	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.18	TNF MMP3 IL1B
23	Allograft rejection ⁷⁴	11.14	TNF MICA IL1B IL13 HLA-DRB1 HLA-C
24	Cytokines and inflammatory response ⁷⁴	11.02	TNF IL1B IL13 HLA-DRB1
25	G-protein signaling_Rap2B regulation pathway ²²	10.92	TNFSF11 TNF LTA IL1B IL13
26	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.7	IL1B IL13

Sources

GO Terms for Psoriatic Arthritis

Cellular components related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.7	TNFSF11 TNF SELE S100A12 MMP3 MIR146A
2	obsolete integral component of lumenal side of endoplasmic reticulum membrane	GO:0071556	9.13	HLA-DRB1 HLA-C HLA-B

Biological processes related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

(show all 32)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.36	CRP IL13 IL1B MIR146A PTPN22 TNF
2	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.22	TNFSF11 TNF S100A12 NOD2 IL1B
3	positive regulation of inflammatory response	GO:0050729	10.21	TNIP1 TNF S100A12 IL1B
4	positive regulation of JNK cascade	GO:0046330	10.19	TNFSF11 TNF NOD2 IL1B
5	positive regulation of I-kappaB kinase/NF-kappaB signaling	GO:0043123	10.18	TNFSF11 TNF S100A12 NOD2 IL1B HLA-DRB1
6	defense response	GO:0006952	10.17	HLA-B NOD2 TNF TNIP1
7	positive regulation of type II interferon production	GO:0032729	10.16	TNF PTPN22 LTA IL1B
8	positive regulation of phagocytosis	GO:0050766	10.13	TNF NOD2 IL1B
9	immune system process	GO:0002376	10.11	S100A12 PTPN22 NOD2 HLA-DRB1 HLA-C HLA-B
10	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.11	TNF PTPN22 IL1B
11	I-kappaB kinase/NF-kappaB signaling	GO:0007249	10.1	TNFSF11 TNF NOD2 IL1B
12	defense response to Gram-positive bacterium	GO:0050830	10.09	CRP IL1B LTA NOD2 TNF
13	regulation of inflammatory response	GO:0050727	10.08	TNIP1 TNF SELE NOD2
14	JNK cascade	GO:0007254	10.08	TNFSF11 TNF NOD2 IL1B
15	cellular response to lipopolysaccharide	GO:0071222	10.07	TNIP1 TNFRSF1B TNF NOD2 MIR146A IL1B
16	inflammatory response	GO:0006954	10.06	TNIP1 TNFRSF1B TNF SELE S100A12 IL1B
17	positive regulation of glial cell proliferation	GO:0060252	10.01	TNF LTA IL1B
18	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	9.99	IL1B TNF TNFRSF1B
19	positive regulation of MAP kinase activity	GO:0043406	9.96	TNFSF11 TNF S100A12 NOD2 IL1B
20	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	GO:0002486	9.95	HLA-C HLA-B
21	positive regulation of fever generation	GO:0031622	9.94	TNF IL1B
22	detection of bacterium	GO:0016045	9.93	NOD2 HLA-DRB1 HLA-B
23	sequestering of triglyceride	GO:0030730	9.92	TNF IL1B
24	immune response	GO:0006955	9.89	HLA-B HLA-C HLA-DRB1 IL13 IL1B LTA
25	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.88	TNF IL1B
26	positive regulation of chronic inflammatory response to antigenic stimulus	GO:0002876	9.87	TNF LTA
27	cell communication	GO:0007154	9.83	TNFSF11 TNF LTA
28	antigen processing and presentation	GO:0019882	9.8	HLA-DRB1 HLA-C HLA-B
29	positive regulation of humoral immune response mediated by circulating immunoglobulin	GO:0002925	9.8	LTA NOD2 TNF
30	leukocyte migration	GO:0050900	9.77	IL1B SELE TNF
31	signaling	GO:0023052	9.75	TNFSF11 TNF LTA
32	response to lipopolysaccharide	GO:0032496	9.44	TNFRSF1B TNF SELE PTPN22 NOD2 LTA

Molecular functions related to Psoriatic Arthritis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide antigen binding	GO:0042605	9.73	HLA-DRB1 HLA-C HLA-B
2	cytokine activity	GO:0005125	9.65	TNFSF11 TNF LTA IL1B IL13
3	tumor necrosis factor receptor binding	GO:0005164	9.63	TNFSF11 TNF LTA
4	TAP binding	GO:0046977	8.92	HLA-C HLA-B